Innovation Award (Cholangiocarcinoma Foundation)

Innovation Award (Cholangiocarcinoma Foundation) is sponsored by Cholangiocarcinoma Foundation. The Innovation Award provides funding for bold ideas and research to transform cholangiocarcinoma care.

**Research Fellowship Awards** Established in 2015, this program supports early-career researchers advancing innovative cholangiocarcinoma research worldwide. CCF has invested over $4. 68 million in seed funding for 81 awardees across 38 institutions in 7 countries.

The program fosters collaboration, data sharing, and progress in understanding and treating the disease. The Innovation Award provides $750,000 over three years to support work in biomarkers for the early diagnosis of cholangiocarcinoma. It funds high-impact ideas with the potential to transform diagnosis and care, improve outcomes, and accelerate the development of new approaches.

Launched in 2025, the Career Development Award provides $300,000 over three years to support mid-career investigators building independent research programs. Funding supports personnel, research, and professional growth to strengthen the pipeline of cholangiocarcinoma researchers.

### Research Fellowship Program In 2015, CCF established a Research Fellowship Program to support early-career, innovative researchers worldwide who are focused on studying cholangiocarcinoma (CCA). The program intends to help these high-quality researchers better understand the complexity of the disease and accelerate the pace of finding a cure. **CCF has invested more than $4.

68 million in seed funding for basic, translational, and clinical research with 81 awards to 38 institutions in 7 countries.

** Applicants Notified of Decision Status of Letter of Intent on November 20, 2026 Full Application Due (for those invited to apply based on the Letter of Intent) January 4, 2027 **Proposal Central Opens for LOI submission: Friday, September 18, 2026** #### CCF Research Fellowship Program CCF chooses grant recipients carefully to ensure they build collaborations between researchers, institutions, and industry and share information, samples, and expertise with others in the field.

Prior experience in the field of cholangiocarcinoma is not required.

Learn more about the program’s research philosophy * Basic Science: Research using laboratory-based models without clinical data from patients * Translational Science: Research studying human samples or data obtained from human samples, annotated with clinical outcome data * Clinical Science: Studies of outcomes in human patients; including population and epidemiology research * Doctor of Veterinary Medicine * Postdoctoral Fellows and Clinical Fellows ##### Institutional Requirements * Academic or medical, or research institutions based anywhere worldwide * Sponsoring institutions must assign a mentor in the proposed research field who assumes responsibility and provides guidance for the research ##### Other Eligibility Requirements * Prior award recipients are eligible to apply * Prior experience in the field of CCA is not required * There are no restrictions for applicants regarding age, gender, race, disability, or national origin/residence * One year of grant support up to $75,000 * Funding for expenses related to the research project, which may include the salary and benefits of the grant recipient, may be used * **CCF will not fund indirect costs or institutional overhead** ##### Letters of Intent Narrative * Research that can impact cholangiocarcinoma patient outcomes * Hypothesis-driven specific aims with well-designed analyses * A feasible project completed within the period of the grant * An identified mentor who will be able to support the project aims and the applicant ##### Evaluation of Letters of Intent * The Letters of Intent (LOI) will be reviewed by the CCF Scientific Review Committee, comprised of established clinical, translational, and basic science researchers, as well as patient research advocates.

Applicants whose LOI is deemed most worthy are invited to submit complete applications ##### Key Components of a Letter of Intent * The LOI should provide a summary of the proposed research project, specific aims and rationale, scientific approach, significance, and innovation (One-page limit) * References (One-page limit) * Applicant NIH Biosketch (preferred) or CV (up to five-pages) * Mentor NIH Biosketch (preferred) or CV (up to five-pages) * Prior awardee only should also provide a progress report and a statement of how the second year of CCF funding would lead to additional support from NIH or other sustained funding (One-page limit) Answers to our most frequently asked questions about the grant application process.

The number of grants in each funding cycle is determined based on the availability of funds. Prior awardees who can demonstrate that additional support is highly likely to lead to further long-term funding will be prioritized. **No, the LOI must be received before the deadline.

** In the Search box, search Cholangiocarcinoma Foundation and click the Apply Now buton to Initiate a Proposal. You can also find the Opportunity by scrolling through the list in the Filter by Grant Maker dropdown. You can access your Saved LOI By clicking on the Identifier number from the Home tab You can also access it via the Proposal tab by clicking on Edit next to the Identifier number.

To delete duplicate Proposals, click the Delete buton in the Proposals tab. If you have problems with the platform, please contact ProposalCentral: * by phone (toll-free):800 875 2562(Toll-free U.S. and Canada) * by or+1 703 964 5840(Direct Dial International) * by email:[[email protected]](https://www. cholangiocarcinoma.

org/cdn-cgi/l/email-protection#f38390808683839c8187b3929f87869edd909c9e) If you have specific questions about the LOI or the program offered by Cholangiocarcinoma Foundation or its guidelines, please contact the CCF Grants manager: [[email protected]](https://www. cholangiocarcinoma.

org/cdn-cgi/l/email-protection#f8aa9d8b9d998a9b90b89b90979499969f91979b998a9b9196979599d6978a9f) The Innovation Award provides $750,000 over three years to fund bold ideas and research to transform cholangiocarcinoma care. The 2027 award will focus on Biomarkers for the Early Diagnosis of Cholangiocarcinoma. LOIs are due Sept.

4, 2026. LOIs are due by Sept. 4, 2026.

Information and instructions are here. Outcome of LOI/Invitation on Sept. 25, 2026 Full Application Due October 28, 2026 Scientific Merit Reviews November 20, 2026 Award Notification November 30, 2026 Earliest Project Start Date June 01, 2027 ### Career Development Award The CDA offers $300,000 over three years to support mid-career investigators establishing independent research programs in cholangiocarcinoma.

2026 awardees have been selected; the 2027 round is not currently open but please check back for future updates